stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) Revenue growth
Takeda Pharmaceutical Co.'s revenue growth over the twelve months to 30 June 2026 was 0.66%, up 2.3 percentage points from fiscal 2026 (−1.66%). Over the past ten years it has ranged from −7.27% (fiscal 2016) to 60.4% (fiscal 2020); the current reading is higher than 33% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 5.22% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2026 | −1.66% | (4.44) |
| FY2025 | 2.78% | 4.07 |
| FY2024 | −1.29% | 4.88 |
| FY2023 | −6.17% | (11.84) |
| FY2022 | 5.67% | 6.39 |
| FY2021 | −0.72% | (61.14) |
| FY2020 | 60.4% | 41.97 |
| FY2019 | 18.5% | 19.53 |
| FY2018 | −1.08% | (8.46) |
| FY2017 | 7.38% | 14.65 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 1.71% | (4.39) |
| Jun 2025 | 6.10% | 6.06 |
| Jun 2024 | 0.04% | 5.16 |
| Mar 2024 | −5.12% | (2.17) |
| 25 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| NBIX Neurocrine Biosciences, Inc. compare | 38.0% |
| ELAN Elanco Animal Health Incorporated compare | 12.0% |
| VTRS Viatris Inc. compare | 4.27% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 2.71% |
| UTHR United Therapeutics Corporation compare | 1.89% |
| ZTS Zoetis Inc. compare | 1.58% |
| TAK Takeda Pharmaceutical Co. | 0.66% |
| RDY Dr. Reddy's Laboratories Ltd compare | −15.5% |
| HLN Haleon PLC Sponsored ADR compare | — |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on TAK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement